论文部分内容阅读
目的:观察奥扎格雷钠联合低分子肝素钙在治疗短暂性脑缺血发作中的临床疗效分析。方法:选取医院2012年2月~2013年2月医院收治的60例短暂性脑缺血发作的患者,随机分为实验组和对照组,每组各30例。两组均给予基础药物和常规治疗,对照组使用低分子肝素钙,实验组在对照组的基础上同时使用奥扎格雷钠注射液静脉滴注。并进行药效评估。结果:用药一个疗程后,对两组患者的情况进行分析,其中实验组总有效率为93.43%,对照组总有效率为72.24%。另外,在两组患者的实验室观察指标中,实验组患者情况也明显优于对照组。结论:奥扎格雷钠联合低分子肝素钙在治疗短暂性脑缺血发作中的临床疗效明显优于单用低分子肝素钙注射液,并且安全性高,不良反应少,值得在临床推广。
Objective: To observe the clinical efficacy of sodium ozagrel combined with low molecular weight heparin in the treatment of transient ischemic attack. Methods: Sixty patients with transient ischemic attack admitted to the hospital from February 2012 to February 2013 were randomly divided into experimental group and control group, with 30 cases in each group. The two groups were given basic drugs and routine treatment, the control group using low molecular weight heparin, the experimental group in the control group based on the use of sodium ozagrel injection intravenous drip. And efficacy evaluation. Results: After a course of treatment, the two groups of patients were analyzed, in which the total effective rate was 93.43% in the experimental group and 72.24% in the control group. In addition, in the two groups of patients with laboratory observations, the experimental group of patients was also significantly better than the control group. Conclusion: The clinical efficacy of sodium ozagrel combined with low molecular weight heparin in treating transient ischemic attack is superior to single low molecular weight heparin injection. It is safe and has few adverse reactions. It is worthy of clinical application.